Arecor Therapeutics to develop intravenous formulation of Par Sterile Products’ medicine
Arecor Therapeutics will develop a ready-to-use formulation of one of Par Sterile Products’ medicines for intravenous use.
The Chesterford Research Park-based biopharmaceutical company has signed a formulation study agreement with Par, an Endo International plc company.
Arecor will use its proprietary formulation technology platform Arestat to develop the differentiated, stable, single dose formulation of the product, which has not been named.
Arecor CEO Sarah Howell said: “We are delighted to be collaborating with Par on an additional programme which further strengthens our track record in developing RTU medicines.
“This growing partnership supports both companies’ product development strategies to bring enhanced products to market that simplify care and improve patient outcomes.
“We believe that our Arestat technology has the potential to deliver a new formulation that can support safe medication practices and improve healthcare efficiency to benefit patients.
“We look forward to developing this relationship with Par which augments our partnership portfolio of major pharmaceutical companies and demonstrates how our formulation expertise can provide novel solutions for our partners.”
The Arestat platform is used to enhance the properties of therapeutic proteins, peptides and vaccines, delivering superior reformulations of existing products and improving properties of products in development.
Sign up for our weekly newsletter and stay up to date with Cambridge life sciences